{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:38:38Z","timestamp":1747147118522,"version":"3.40.5"},"reference-count":22,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High\u2010dose methylprednisolone plus rituximab (R\u2010HDMP) is a useful treatment in chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL) patients unfit for chemo\u2010immunotherapy and has proven its utility on the treatment of CLL\/SLL complicated by auto\u2010immune cytopenias. We performed a retrospective, single\u2010centre study, of CLL\/SLL patients treated with R\u2010HDMP for 9\u00a0years. Thirty\u2010nine patients were included, median age at time of treatment was 77\u00a0years. Most patients had stage Rai III\/IV and Binet C disease. Twenty\u2010eight patients had relapsed\/refractory disease at time of treatment with a median of 1 previous line of therapy; 53.8% had prior exposure to fludarabine and 25% to rituximab. Grade 3\u20134 neutropenia and thrombocytopenia were recorded in 10.2% and 17.9% patients, respectively. While on treatment, 51.3% had documented infectious complications, but no other non\u2010haematological toxicities grades 3\u20134 were identified. Overall response rate was 64%. Median overall survival and progression\u2010free survival were 24 and 13\u00a0months, respectively. Twenty four patients relapsed and 16 received another line of treatment after R\u2010HDMP, with median time to next treatment of 13.5\u00a0months. Thirteen out of the 24 patients improved performance status and were subsequently considered fit for chemo\u2010immunotherapy. R\u2010HDMP is a valuable option for elderly and frail patients, with low risk of severe myelotoxicity and other severe adverse events. It was shown to work as a bridge to other lines of treatment, including chemo\u2010immunotherapy.<\/jats:p>","DOI":"10.1002\/cam4.4374","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T08:56:23Z","timestamp":1637052983000},"page":"8768-8776","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chronic lymphocytic leukaemia\/small lymphocytic lymphoma treatment with rituximab and high\u2010dose methylprednisolone, revisited"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-7746","authenticated-orcid":false,"given":"Ana","family":"Vagos Mata","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Espada","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"},{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes Faculdade de Medicina Universidade de Lisboa Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Alves","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Polo","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concei\u00e7\u00e3o","family":"Lopes","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"F. Lacerda","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"},{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes Faculdade de Medicina Universidade de Lisboa Lisbon Portugal"},{"name":"Faculdade de Medicina Universidade de Lisboa Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Raposo","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Department Hospital de Santa Maria Centro Hospitalar Universit\u00e1rio Lisboa Norte Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.1016\/j.medcli.2016.12.030"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1182\/blood-2017-09-806398"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.3324\/haematol.2010.036152"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.3389\/fonc.2019.01435"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.1080\/10428190902919226"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1111\/j.1365-2141.2008.07086.x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_8_1","DOI":"10.1016\/j.beha.2010.01.004"},{"doi-asserted-by":"publisher","key":"e_1_2_8_9_1","DOI":"10.1002\/ajh.25595"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1517\/14740338.2013.827660"},{"doi-asserted-by":"publisher","key":"e_1_2_8_11_1","DOI":"10.1056\/NEJMoa1815281"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.1182\/blood-2019-126686"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1093\/annonc\/mdw547"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.3109\/10428199909083393"},{"doi-asserted-by":"publisher","key":"e_1_2_8_15_1","DOI":"10.5114\/aoms.2016.55425"},{"issue":"11","key":"e_1_2_8_16_1","first-page":"1","article-title":"Dose intensive rituximab and high\u2010dose methylprednisolone in elderly or unfit patients with relapsed chronic lymphocytic leukemia","volume":"55","author":"Pileckyte R","year":"2019","journal-title":"Medicina (Kaunas, Lithuania)"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.1080\/10428190701724801"},{"doi-asserted-by":"publisher","key":"e_1_2_8_18_1","DOI":"10.1038\/leu.2009.133"},{"doi-asserted-by":"publisher","key":"e_1_2_8_19_1","DOI":"10.1002\/cncr.31554"},{"doi-asserted-by":"publisher","key":"e_1_2_8_20_1","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792"},{"key":"e_1_2_8_21_1","article-title":"The cost\u2010effectiveness of ibrutinib in treatment of relapsed or refractory chronic lymphocytic leukemia","volume":"2","author":"Sorensen SV","year":"2016","journal-title":"Health Econ Outcome Res"},{"doi-asserted-by":"publisher","key":"e_1_2_8_22_1","DOI":"10.1182\/blood-2016-12-737346"},{"doi-asserted-by":"publisher","key":"e_1_2_8_23_1","DOI":"10.1002\/ajh.25638"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4374","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:02:09Z","timestamp":1693198929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":22,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/cam4.4374"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4374","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"2021-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}